NCT03755791Phase 3Active not recruiting

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy

Study sponsor: Exelixis

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2021-11-30Actual
Enrollment · participants837Actual
Source updated2025-12-11Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: 8 Mar 2021. After: 30 Nov 2021.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Duration of Progression Free Survival (PFS) for the experimental arm vs. the control arm Measure: Duration of Overall Survival (OS) for the experimental arm vs. the control arm. After: Measure: Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population Measure: Overall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Population.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview